IDS and neoplasm: Of note, this cellular phenotype was comparable with the metabolic subtype (MPS2) proposed by Gong et al., and inhibiting lactate dehydrogenase could improve response to anti–PD-1 therapy and increase the anti-tumor immune response within this subtype24.